Small Pharma Inc. (DMTTF)
Small Pharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GB. The stock last traded at $0.11, down 9.69% on the session, giving a market capitalisation of $37.5M. On trailing twelve-month figures it carries a trailing P/E of -2.19, a net margin of 0.0%. Its beta of 0.85 implies it has historically moved less than the broad market.
Small Pharma Inc. is a biotechnology firm focused on developing fast-acting psychedelic therapies, coupled with supportive psychological care, to address mental health conditions. Its flagship clinical initiative centers on N,N-dimethyltryptamine (DMT) assisted therapy designed to combat major depressive disorder. Specifically, its compound SPL026 is currently in Phase IIA clinical trials for MDD treatment. The company's preclinical pipeline also includes SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801, an oral formulation of 6-hydroxynorketamine. Founded in 2015, Small Pharma Inc. is headquartered in London, United Kingdom.
Small Pharma Inc. is most often compared with the following Healthcare names: